Medical treatment of renal cancer: New horizons

British Journal of Cancer

Volumn 115, Issue 5, 2016, Pages 505-516

  Greef, Basma ^a   Eisen, Tim ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

systemic therapy; metastatic renal cell carcinoma; T cell checkpoint inhibitors; tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CANCER VACCINE; INTERLEUKIN 2; TUMOR MARKER;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL (TOPIC); CYTOREDUCTIVE SURGERY; EARLY CANCER; HUMAN; INTERMEDIATE RISK PATIENT; KIDNEY CANCER; KIDNEY METASTASIS; NEPHRECTOMY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL RATE;

EID: 84982957509     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.230     Document Type: Review

References (82)

1. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, MacKenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan M-H, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY. (2013). The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGFtargeted therapy in metastatic renal cell carcinoma patients. Target Oncol 8: 203-209
2. Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DYC, Dariane C, DeVelasco G, Lester R, Escudier B, Choueiri TK. (2015). Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. Eur J Cancer 51: 2580-2586
3. Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Knox JJ, Pal SK, Henner Voss M, Sharma P, Kollmannsberger CK, Heng DYC, Spratlin JL, Shen Y, Kurland JF, Gagnier P, Hammers HJ. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 32(5s Suppl): (abstract 5010
4. Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ. (2016). Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol 17: 378-388
5. Asimakopoulos AD, Miano R, Annino F, Micali S, Spera E, Iorio B, Vespasiani G, Gaston R. (2014). Robotic radical nephrectomy for renal cell carcinoma: a systematic review. BMC Urol 14: 75
6. Batelli C, Cho DC. (2011). mTOR inhibitors in renal cell carcinoma. Therapy 8: 359-367
7. Bjarnason GA, Khalil B, Hudson JM, Williams R, Milot LM, Atri M, Kiss A, Burns PN. (2014). Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol 32: 480-487
8. Cancer Research UK. (2016). Kidney Cancer Stastistics. Available at http://www.cancerresearchuk.org/health-professional/cancer-statistics/statisticsby-cancer-type/kidney-cancer (accessed on 05/04/2016
9. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee J-L, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DYC, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ. (2015). Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373: 1814-1823
10. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin M-L, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA. (2010). Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363
11. Dickerson EC, Davenport MS, Liu PS. (2015). Spontaneous regression of primary renal cell carcinoma following image-guided percutaneous biopsy. Clin Imaging 39: 520-524
12. Dudek A, Sica R, Sidani A, Gopalji Jha G, Xie H, Shivaram Alva A, Stein M, Singer E. (2016). Phase Ib study of pembrolizumab in combination with bevacizumab for the treatment of metastatic renal cell carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003. J Clin Oncol 34(2s Suppl): (abstract 559
13. Duns G, van den Berg E, van Duivenbode I, Osinga J, Hollema H, Hofstra RM, Kok K. (2010). Histone Methyltransferase Gene SETD2 is a Novel Tumor Suppressor Gene in Clear Cell Renal Cell Carcinoma. Cancer Res 70: 4287-4291
14. Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G. (2009). Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26: 202-209
15. Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI. (2014a). Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 110: 2821-2828
16. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111
17. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. (2014b). Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 32: 1412-1418
18. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A. (2014c). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(S3): iii49-iii56
19. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R. (2008). Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14: 6674-6682
20. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. (2004). Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171: 1071-1076
21. Fyfe GA, Risher RI, Rosenberg SA, Sznol M, Parkinson DR. (1996). Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 14: 2410-2411
22. Gerety EL, Lawrence EM, Wason J, Yan H, Hilborne S, Buscombe J, Cheow HK, Shaw AS, Bird N, Fife K, Heard S, Lomas DJ, Matakidou A, Soloviev D, Eisen T, Gallagher FA. (2015). Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99m Tc-MDP bone scintigraphy, using an adaptive trial design. Ann Oncol 26: 2113-2118
23. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892
24. Gibney GT, Aziz S a., Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. (2013). C-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 24: 343-349
25. Gossage L, Eisen T, Maher ER. (2015). VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15: 55-64
26. Gossage L, Murtaza M, Slatter AF, Lichtenstein CP, Warren A, Haynes B, Marass F, Roberts I, Shanahan SJ, Claas A, Dunham A, May AP, Rosenfeld N, Forshew T, Eisen T. (2014). Clinical and pathological impact of VHL, PBRM1, BAP1 SETD2, KDM6A and JARIDIc cell renal cell carcinoma. Genes Chromosomes Cancer 53: 38-51
27. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. (2008). Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34: 193-205
28. Haas NB, Manola J, Uzzo RG, Atkins MB, Wilding G, Pins M, Jewett MAS, Kane CJ, Cella D, Wagner LI, Coomes B, Wood CG, Dutcher JP, Flaherty K, DiPaola RS. (2015). Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavourable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol 33(Suppl 7): (abstract 403
29. Haas NB, Nathanson KL. (2014). Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis 21: 81-90
30. Hakimi AA, Chen Y-B, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, Voss MH, Motzer RJ, Coleman JA, Cheng EH, Russo P, Hsieh JJ. (2013). Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 63: 848-854
31. Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Ernstoff MS, Henner Voss M, Sharma P, Kumar Pal S, Razak AR, Kollmannsberger CK, Heng DYC, Spratlin JL, Shen Y, Gagnier P, Amin A. (2015). Expanded cohort results from CheckMate016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 33(Suppl): (abstract 4516
32. Hemal AK, Kumar A. (2009). A prospective comparison of laparoscopic and robotic radical nephrectomy for T1-2N0M0 renal cell carcinoma. World J Urol 27: 89-94
33. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27: 5794-5799
34. Heng DYC, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. (2013). External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. Lancet Oncol 14: 141-148
35. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. (2007). Five-year survival after surgical treatment for kidney cancer: A population-based competing risk analysis. Cancer 109: 1763-1768
36. Hu M, Sun X-J, Zhang Y-L, Kuang Y, Hu C-Q, Wu W-L, Shen S-H, Du T-T, Li H, He F, Xiao H-S, Wang Z-G, Liu T-X, Lu H, Huang Q-H, Chen S-J, Chen Z. (2010). Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling. Proc Natl Acad Sci USA 107: 2956-2961
37. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, Mcdermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IGH, Barbarash O, Gokmen E, Toole TO, Lustgarten S, Moore L, Motzer RJ. (2007). Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. N Engl J Med 356: 2271-2281
38. Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. (2015). Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 26: 1128-1133
39. Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, Frenkel E, Parker AS, Brugarolas J. (2016). Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J Urol 195: 180-187
40. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. (2013). Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 14: 159-167
41. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. (1998). Resection of metastatic renal cell carcinoma. J Clin Oncol 16: 2261-2266
42. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH. (2009). Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15: 2148-2157
43. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur G, Ascierto P, Long G, Callahan M, Postow M, Grossman K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin L, Horak C, Hodi F, Wolchok J. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34
44. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. (2003). Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97: 1663-1671
45. Li H, Samawi H, Heng DYC. (2015). The use of prognostic factors in metastatic renal cell carcinoma. Urol Oncol 33: 509-516
46. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TBL, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Canfield SE, McClinton S, Griffiths TRL, Ljungberg B, N'Dow J. (2012). Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol 61: 972-993
47. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MKK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. (2015). The High-dose aldesleukin 'select? trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 21: 561-568
48. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik O-PR, Sabbisetti VS, Bhatt RS, Simantov R, Choueiri TK. (2015). Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 21: 2471-2479
49. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. (2015). Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poorrisk metastatic renal cell carcinoma. Cancer 121: 3435-3443
50. Motzer BRJ, Bacik J, Murphy B a, Russo P, Mazumdar M. (2002). Interferon-Alfa as a Comparative Treatment for Clinical. J Clin Oncol 20: 289-296
51. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu L-A, Waxman IM, Sharma P. CheckMate 025 Investigators. (2015a). Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373: 1803-1813
52. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 372: 449-456
53. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. (2013). Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369: 722-731
54. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim H-J, Wood K, Dutcus C, Larkin J. (2015b). Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16: 1473-1482
55. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
56. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540
57. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grünwald V, Davis ID, Lee J, Esteban E, Sklodowska-curie M. (2014). Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 15: 286-296
58. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. (2015c). Nivolumab for metastatic renal cell carcinoma: results of a randomized phase ii trial. J Clin Oncol 33: 1430-1437
59. Pal SK, Haas NB. (2014). Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist 19: 851-859
60. Pena-LLopis S, Christie A, Xie X-J, Brugarolas J. (2013). Co-operation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res 73: 4173-4179
61. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, Kinch L, Hambuch T, Jain S, Lotan Y, Margulis V, Sagalowsky AI, Summerour PB, Kabbani W, Wong SWW, Grishin N, Laurent M, Xie X-J, Haudenschild CD, Ross MT, Bentley DR, Kapur P, Brugarolas J. (2012). BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 44: 751-759
62. Pham A, Ye D-W, Pal S. (2015). Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma. Urol Oncol 33: 517-527
63. Raman R, Vaena D. (2015). Immunotherapy in metastatic renal cell carcinoma: a comprehensive review. Biomed Res Int 2015: 367354
64. Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, Campbell S, Elson P, Koscielny S, Lopatin M, Svedman C, Martini J-F, Williams JA, Verkarre V, Radulescu C, Neuzillet Y, Hemmerlé I, Timsit MO, Tsiatis AC, Bonham M, Lebret T, Mejean A, Escudier B. (2015a). A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol 16: 676-685
65. Rini B, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb S, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Mahr A, Fritsch J, Weinschenk T, Singh H, Kirner A, Reindhardt C, Eisen T. (2015b). Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. Eur J Cancer 51(Suppl 3): S718 (abstract 17LBA
66. Rini BI, Campbell SC, Escudier B. (2009a). Renal cell carcinoma. Lancet 373: 1119-1132
67. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin R a., Baum MS, Motzer RJ. (2011a). Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103: 763-773
68. Rini BI, Dorff TB, Elson P, Suarez C, Humbert J, Pyle L, Larkin J, Plimack ER. (2014). A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy. J Clin Oncol 32(5s Suppl): (abstract 4520
69. Rini BI, Escudier B, Hariharan S, Roberts WG, Tarazi J, Rosbrook B, Askerova Z, DeAnnuntis LL, Motzer RJ. (2015c). Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 13: 540-547
70. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou Y-C, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. (2011b). Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939
71. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou S-S, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. (2008). Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26: 5422-5428
72. Rini BI, Quinn DI, Baum M, Wood LS, Tarazi J, Rosbrook B, Arruda LS, Cisar L, Roberts WG, Kim S, Motzer RJ. (2015d). Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol 10: 45-53
73. Robson CJ, Churchill BM, Anderson W. (1969). The results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297-301
74. Russo P, Jang TL, Pettus JA, Huang WC, Eggener SE, O?Brien MF, Karellas ME, Karanikolas NT, Kagiwada MA. (2008). Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer 113: 84-96
75. Sacré A, Barthélémy P, Korenbaum C, Burgy M, Wolter P, Dumez H, Lerut E, Loyson T, Joniau S, Oyen R, Debruyne PR, Schöffski P, Beuselinck B, Sacré A, Barthélémy P, Korenbaum C, Burgy M, Wolter P, Dumez H, Lerut E, Loyson T, Joniau S, Oyen R, Debruyne PR, Schöffski P, Beuselinck B, Korenbaum C, Burgy M, Wolter P, Dumez H, Sacre A. (2016). Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor receptor tyrosine kinase inhibitor. Acta Oncol. 55(3): 329-340
76. Shablak A, Sikand K, Shanks JH, Thistlethwaite F, Spencer-Shaw A, Hawkins RE. (2011). High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother 34: 107-112
77. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068
78. Stewart SB, Thompson RH, Psutka SP, Cheville JC, Lohse CM, Boorjian SA, Leibovich BC. (2014). Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. J Clin Oncol 32: 4059-4065
79. Tunuguntla HSGR, Jorda M. (2008). Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 179: 2096-2102
80. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin M-L, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LFA, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chanon W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA. (2011). Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539-542
81. Wolter P, Dumez H, Schoffski P. (2007). Suntinib and Hypothyroidism. N Engl J Med 356: 1580
82. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE. (2009). Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 15: 7582-7592